|
Kallmann Syndrome
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome.
|
22927827 |
2012 |
|
Kallmann Syndrome
|
0.360 |
Biomarker
|
disease |
BEFREE |
SEMA3A and SEMA7A were screened by Sanger sequencing in altogether 50 Finnish HH patients (34 with Kallmann syndrome (KS; HH with hyposmia/anosmia) and 16 with normosmic HH (nHH)).
|
24522099 |
2014 |
|
Kallmann Syndrome
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
By analyzing protein expression and processing, we did not observe any differences of the p.I668V variant compared with wild-type SEMA3A, while a pathogenic SEMA3A variant p.R66W recently described in a patient with Kallmann syndrome did affect protein secretion.
|
29432577 |
2018 |
|
Kallmann Syndrome
|
0.360 |
Biomarker
|
disease |
BEFREE |
SEMA3A is therefore a new gene whose loss-of-function is involved in KS.
|
22416012 |
2012 |
|
Kallmann Syndrome
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
By performing knockdown experiments for Chd7 in Xenopus laevis embryos, we found abnormalities in the expression pattern of Sema3a, a protein involved in the pathogenesis of Kallmann syndrome, in vivo.
|
24728844 |
2014 |
|
Kallmann Syndrome
|
0.360 |
Biomarker
|
disease |
BEFREE |
Strikingly, mice lacking SEMA3A or semaphorin signalling through both NRP1 and NRP2 recapitulate the anatomical features of a single case of KS analysed so far, and may therefore be used as genetic models to elucidate the pathogenesis of KS.
|
21059704 |
2011 |
|
Malignant neoplasm of breast
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Among 1,980 breast cancer cases from a public database, the ratio of VEGF and SEMA3A in primary tumors (n = 450) of hormone-receptor-negative breast cancer is associated with ARHGAP17 expression inversely, and with disease free survival.
|
29971782 |
2018 |
|
Malignant neoplasm of breast
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Stilbenoid-Mediated Epigenetic Activation of Semaphorin 3A in Breast Cancer Cells Involves Changes in Dynamic Interactions of DNA with DNMT3A and NF1C Transcription Factor.
|
31327173 |
2019 |
|
Schizophrenia
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
The PLXNA2 ligand semaphorin 3A has been shown to be upregulated in the cerebellum of individuals with schizophrenia.
|
16402134 |
2006 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
BEFREE |
The results show that sema3A is elevated in schizophrenia, and is associated with downregulation of genes involved in synaptic formation and maintenance.
|
12610647 |
2003 |
|
Alcoholic Intoxication, Chronic
|
0.110 |
Biomarker
|
disease |
BEFREE |
SEMA3A variation is significantly and replicably associated with comorbid AD and MD in African American participants.
|
29071344 |
2017 |
|
Hypogonadotropic hypogonadism
|
0.110 |
AlteredExpression
|
disease |
BEFREE |
Chd7 regulates the expression of Sema3a, which also contributes to the pathogenesis of Kallmann syndrome, a heterogeneous condition with the typical features hypogonadotropic hypogonadism and an impaired sense of smell.
|
29432577 |
2018 |
|
Major Depressive Disorder
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
SEMA3A variation is significantly and replicably associated with comorbid AD and MD in African American participants.
|
29071344 |
2017 |
|
Sense of smell impaired
|
0.110 |
Biomarker
|
phenotype |
BEFREE |
SEMA3A and SEMA7A were screened by Sanger sequencing in altogether 50 Finnish HH patients (34 with Kallmann syndrome (KS; HH with hyposmia/anosmia) and 16 with normosmic HH (nHH)).
|
24522099 |
2014 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that measurement of sema3A serum concentrations may be of use for the diagnosis and for the monitoring of malignancies of the bone marrow such as MM.
|
30102336 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Higher sema3A values were significantly correlated (P = 0.006) with presence of urothelial cancer, as determined by positive cystoscopy or urethroscopy and pathological biopsy.
|
29288007 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results indicate that miR-192-5p contributes to targeting SEMA3A in HCCLM3 cells, and this may be used as a target in targeted therapy and a marker for cancer behavior and prognosis.
|
26580097 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Semaphorin3a (sema3a), a member of class 3 semaphorins, is a guidance protein that regulates angiogenesis, branching morphogenesis, axon growth, and cell migration, and has pleiotropic roles on organogenesis, immune response, and cancer.
|
24464477 |
2014 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In human breast cancer specimens, we found that immunohistochemical levels of SEMA3A correlated with the expression of genes characteristic of M1 macrophages, CD8(+) T cells, and NK cells, while inversely correlating with established characters of malignancy.
|
27197153 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on human tumor gene expression databases, HMGB1 was significantly inversely correlated with SEMA3A, suggesting that this mechanism may be more widely relevant in different cancer types.
|
24213571 |
2014 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although NP1 is expressed in carcinoma cells, its functions have remained elusive, and neither SEMA3A nor plexin expression has been explored in cancer.
|
14500350 |
2003 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In summary, mutant SEMA3A is a vascular normalizing agent that can be exploited to treat cancer and, potentially, other diseases characterized by pathological angiogenesis.
|
29794061 |
2018 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression levels of SEMA3A were lower in the cancer tissues with III/IV stage [the International Federation of Gynecology and Obstetrics (FIGO) stage], poor histological grade, lymph node metastasis and distant metastasis compared to that in the cancer tissues with I/II stage (FIGO), well histological grade, or without lymph node metastasis and distant metastasis (P<0.05).
|
25812535 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collapsin response mediator protein (CRMP) family proteins are cytosolic phosphoproteins involved in semaphorin 3A-mediated neuronal cell growth cone collapse and cancer invasion.
|
19362386 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data suggest that the downregulated expression of SEMA3A and several SEMA3s results in a loss of inhibitory activities in tumor angiogenesis and tumor growth of VEGFA; therefore, it may play an important role on the pathogenesis of the epithelioid type of MM.
|
21842119 |
2011 |